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the efficacy :I allepk for coronary 
lhromkdvsh in palienb wilh acute mwardial infarction. In this 
sludy we~exnmirkd the relation b&n the level of inlravenous 
anticuagulation with hepmin and sustained coronary artery pa- 
tency in a subgroup of patients oftbe Europan Crmpnti*e Study 
Croup (ECSG) trial. 
M~tJmds. In the ECSG trial, patients reated with altepiase and 
aspirin were randomized to concomitant fixed doses of inlraw 
nous bepwbt (a bolos do?& of 5,000 U followed by B continuous 
illusion of LOW Uib 01 otnrrbo). Tbe current study eraun 
who bad both m interpretable mronnry aagiayam obtained 
within 6 days of treatment and stiricnt plasma samples lo auw 
lbe level 01 atticoaeulatiin. Activated oartial lhrombod~tin 
lines, fibrinogen attdD-diner Wets &determiwd w hama 
spmptes al besetine and ~145 min and 3,IZtz nnd 36 b nller lbe 
SLlrl ol allqdase adndnislralii. 
RcsnUs. The curonrry a&y patency rate was higher in 
patients aWaled to bepario therapy than in those alkwated to 
placebo (80% and 71%, respwtivety, p = 0.05). Patienb atlaealrd 
intravenous thmmbolytic therapy with streptokinase, al- 
teplase or anistreplase reduces mortality in patients with 
evolving acute myocardial infarction (l-4). However, the 
optimal regimen for thmmbolytic therapy has yet to he 
defined. In particular, the need for continued anticoagulation 
after thrombolydc therapy remains uncertain. Administra- 
tion of heparin to patients treated with allepkise does not 
further improve coronary artery patency as determined 
by coronary angiography at 90 min (5). However. among 
10 brpari” were da&ied into lbrrr subgroups: ‘# pattents ,3290, 
with all activated @iat tbmanbo@atin tbws at lead twice lhpir 
own baseline valae loptitwl a&owdatW, 40 patients (27%) 
nith the lowest aclivatmt pa&l lhraaboplaain tinw al 3, 12.24 
or 36 h betwee” JMB and 260% oltbe bawtii value ~subopimat 
antic0a@datkm, and 61 *ls wab at tca?lo5e nedvatfd partial 
tion). In’the beparin group, comnary artery &WY co&ted 
with the level of nntkw@aliw: 98%. 88% awl 72% respec 
tiwly, In patienls with @mat, s~boptirrul and bwkqwsle arali- 
.xJamdalian ,c = o.oL wbll?J “I. blaaauru ardk~~,. 
patients given alteplare. the patency rate after I8 h (6). 57 h 
(7) or 2 to 5 days (8) was higher in those with than in those 
without additi&d concomitant reatment with intravenous 
heowin. Althoueh different doses of aspirin were given in 
these three stud& (80 mg, nor.e and 325 &day, res&ciive- 
ly), the results support the hypothesis that intweoous 
heparin improves ustained coronary artery patency induced 
with olteplase. In the European Cooperative Study Group 
(EC%) trial (8). fixed doses of hepain were used to 
maintain double blinding in comparison with placebo. Be- 
CZW? !hr xauz! nC hepatio needed to achieve adequate 
anticoagulation varies among subjects, it is likely that fixed 
heparin doses will result in optimal anticoagulation in som 
patients and in inadequate anticoagulation in others. There- 
fore, in the present study. the relation between the level of 
intravenous anticoagulation, as monitored by activated par- 
tial thromhoplastin lime assays, and subsequent coronary 
artery patency was analyzed in a representative subset of 
Table 1. Iwient Entry 
patients in the ECSG trial treated with alteplase and aspirin 
and concomilanl fixed dose intravenous heparin or placebo 
(8). 
Methods 
Patient selection and treatment. Coagulation measure- 
ments were performed in a subset of natients in the he&n 
trial of the European Cooperative S;udy Group (ECSG.6) 
(Table 1). Patients aaed 21 to 70 “ears were recruited 
according to well defined selection cril&ia similar to those in 
other European Cooperative Study Group trials (9-11). All 
patients were treated with alceplase. 100 mg (Actilyse, 
Boehrinaer tngetheim, Inaelheim, Germany) administered 
intravenously as a I&ng bolur dose followed by 50 ma over 
the 1st hand 40 mg over the next 2 h, and with aspirin, either 
as a 250.mg intravenous bo!us dose (continental centers) or 
3W mg orally (United Kingdom center) followed by 75 to 
125 mg on alternate days in all centers. Patients randomized 
to hepsrbr therapy were given an intravenous bolus dose of 
S&M U immediately after randomization followed bv an 
infusion d I.ooO U/h. This dose remained unchanged~and 
adjustment of the heparin dose according to hemostasis 
measurements was not allowed until -onmary engiography. 
After angiography, investigators were free to continue or 
discontinue heparin administration. Heparin placebo (dilute 
albumin solution! wa5 prepared in i+n!ice! vials ard given in 
the same way to patients randomized to placebo. Atl suh- 
jecls entered into ibis study awe iniormed eonsent, and the 
study protocol has been approved by the institutional com- 
mittees on medical research. 
Study end points. The primary end point of the heparin 
trial of the European Cooperative Study Group was core. 
nary artery patency as documented by angiography per. 
farmed between 48 and I20 h after the onset ofthrombnlytic 
treatment. Secondary end points included recurrent isch- 
emia and reinfarction (see later) and bleeding complications. 
The present analysis focuses on the contribution of the level 
of anticoagulation, as assessed by serial activated partial 
thromboplastin measurements, to primary and secondary 
end ooints. 
Btwd sampling and handling. The first 400 patients of a 
total of 652 patients from 19 centers in six European eoun- 
tries were scheduled for serial blood sampling. Blood sam- 
ples were drawn before treatment allocation (baseline) and at 
45 min, 3 h (end of alteplase infusion), 12 h. 24 h and 36 h 
after initiation of thrombolvtic theraov. Tubes for blood col- 
lection contained 0.5 ml oi sodium &ate (final concentra- 
tion 0.01 I mollliter). and either aprotinin (final cancentratinn 
ISO klUlmt) oro-phenylalanyl-prolyl-arginine-chloromethyl- 
ketone (PPACK. final concentration 0.002 mmohliter) as. 
respectively, thmmbin (12) and alteplaac (13) inhibitor. 
Venous blood was collected fmm a free-flowing needle and 
without lourniquet, if possible. Sampling from iedwelling 
catheters was allowed after the first IO ml of blood was 
discarded. Within 20 ndn af blood callection the tubes were 
centrifuged at 2,wO g for 10 to 20 min and the platelet-poor 
olasma was stored below -20°C. For assessmest ofthe level 
bf anticoagulation, the baseline plasma sample and at least 
two of the four samoles scheduled at 3. 12.24 and 36 h after 
the onset of alteplak administration &er&uired. 
Hemoatasfs analyses. All laboratory analyses wcn. per- 
formed centrally at the Center fur Thmmbos;s cud Vascular 
Research. Leuven. Belgium without knowledge of clinical or 
angiographic data. Activated partial thromboplastfn times 
were determined in plasma samples collected on citrate and 
aprotinin, on an automated coagulation analyzer (ACL 610, 
Instrumentation Laboratory, Milan, Baly) with use of a 
microniaed silica activated partial thromboplastin time re- 
agent (Instrumentation Laboratory). The level of anticoagu- 
lation WBE assessed on the basis of the activated partial 
thromboplastin times of the samples collected 3. 12. 24 and 
36 h after initiation of therapy. Optimd onricongulotion was 
defined as no activated partial thromhoplastin time <ZOG% 
of the patient’s own baseline value in any sample collected at 
3, 12. 24 or 36 h after initiation of therapy. Patients were 
considered to have saboprinol nnticoagrtlotion when the 
lcwest activated partial thromhoplartin time at 3. 12, 24 or 
36 h was 130% to 200% of the baseline value. Patients were 
defined to have i:radequure an:icnogzlnl~on when the short- 
est activated partial thromboplaslin time was <l30% of the 
baseline value. 11 should be noted that the activated partial 
lhromboplastin time, although generally used to assess the 
intensity of hemin therapy durinr: therapeutic thrombolv- 
sis, c&also bk prulongedby tib&ogen hegradation proh- 
ucts or by inactivation of eaa!&tion Factcr$ V 2nd VIII 
resulting from systemic plas& generation and alpha, 
antiplasmin depletion. 
Fibrinogen was determined on plasma collected on citrate 
and apmtinin by a fibrin polymerization time method (14) 
with use of a semiautomated coagulation instrument (KC IO. 
Ameluna. Germany). Ddimer levels were determined in 
plasma &mpks c&ted on citmte and o-phenylalanyl- 
~rolyl-arsinine-chloromethylketane with use of a sandwich 
&&me-inked immunoso&nt assay (ELlSA) based on a 
fibrin fragment Ddimer-specific capture monaclonal anti- 
body and a fibrin fragment D-specific tag antibody (1% 
Coronary angiogrrpby. Coronary angiography was xhed- 
uled between 2 and 5 days after the start of thromholytic 
treatment. In the present ancillary study all patients were 
included who had angiogmphy within 6 days after allccation. 
The patency of the infarct-related vessel was assessed by 
a patIe of iive observers who had no knowledge of treatment 
allocation. Results are reponed as Thrombolysis in Myocar- 
dial Infarction (TIMI) flow grades (16). Patients who were 
given a second dose of altcplase for clinical signs of reoc- 
elusion before the scheduled coronary angiography were 
considered tc have TIM1 grade 0 flow for the present 
analysis, irrespective of the result of angiography. If angio- 
plasty had been performed, only the aagiographic results 
obtainef before this intervention were used in this study. 
Recurrent i&emia and r&tfardion. Clinical. electrocar- 
diographic and ~emm enzyme evidence of recurrent isch- 
wtia and reinfarctinn WPT~ reviewed by an independent 
clinical ssnt committee. Recurrent is:hemic events were 
clasrilied as reiniarction (characterized by recurrent in- 
crease in cardiac enzyme levels). unstable angina (angina 
with dynamic ST segment changes without enzyme increase) 
or other chest pain. Repeated administration of alteplase for 
clinical signs of reocclusion was allowed by the protocol. 
Bleeding eomPikationr. Hemorrhagic complications were 
recorded in detail on case report forms according to preset 
criteria. Major hemorrhagic comp!ica!ions (need for trsnsfu- 
sion, intracranial hemorrhage, retmperitoneal bleeding) 
were reviewed and further investigated by a central clinical 
events committee. 
Statistical aitaly+ Analysis was performed with the 
Statistical Analysis System (SAS). version 6.09 on an IBM 
computer. The Fisher exact test was applied to catewic 
variahler and the Wilcoxon rank sum test (Mann-Whitney) 
was used to compare numeric data between patient groups. 
A total of 652 patients were included in the heparin trial, 
of ahom 8 were excluded from analysis because oftechn:cal 
or administrative reaxms (8). Of the tint 403 patients xhed- 
uled to enter the present substudy. 281 patients had adeqoale 
angiograms and a sufficient number of activated partial 
thromboplastin times available for the analysis. A complete 
set of activated partial thromboplastin times was available in 
81% of the sslectcd patients; 15% of the patients had only 
one activated partial thromboplastin time lacking. Of the 281 
patients included in this study, 13 received a second dose of 
alteplase before angkwaphy because of clinical signs of 
reocclusion (pain with ST segment elevation). There were 
149 patients allocated to concomitant hepatin therapy and 
132 patirnls assigned to placebo (Table I). Baseline charac- 
teristics m these two groups were well balanced (Table 2) 
and indistinguishable fmm those of the total population of 
Ihe Eumpean Cmperative Study Group hetwin trial de- 
scribed elsewhere (8). Although all patients allocated to 
heparin therapy received a 5.~U hepatio bolos and a 
continuous infusion of I,lHlJ U/h. an optimai level of anti- 
coagulation, as specified in the Methods section, was 
achieved in only 48 (32%) of the 149 patients; 40 (27%) had 
a suboptimal tevet of anticoagulation and 61 (41%) had 
inadequate anticoagulation. Baseline characteristics were 
similar in these three subgroups (Table 2). 
Hemostatic wiables. Baseline (time 0) activated partial 
thromboplastin times, fibrinogen and D-dimer levels did not 
differ between patients allocated to placebo 01 heparin. 
Toward [be end of the infusion of alteplase (time = 3 hl, 
activated parlial thromhoplartin limes were prolonged in 
both the heparin and placebo groups (Fig. I). By definition, 
after I2 h, the activated partial ~lhromhoplastin time re- 
mained prolonged in the subgroup of patients with optimal 
anticoagulation, whereas the value returned to near baseline 
levels in patients with inadequate ~~ticoagulation. 
During alteplase infusion, fibrinogen l&Is were reduced 
in both croups, to 65% and 60% at 3 h in the he&n and 
placebogro~ps, respectively (Fig. 2,; thereafter, a gradual 
recovery of fibrinogen levels was observed. Fibrinogen 
levels did not correlate either with the level of anticoagula- 
Lion or with coronary artery patency. 
Most of the study patients l7W had normal D-dimer 
Figure Z. Wxmogen kvel, ,mcdian * 5 to 95 percemdes~ B, “, 0.75, 
3. 12. 24 and 36 h in bosh treatment groups. The heparin group is 
subdivlded on the b&s of the activated panial thromboplastin limes 
(see Rg. 1 for numhcra and posilion of percenlile? in dilkrent 
grOUpSI. 
Figure 3. Ddimer Ievels In&/ml; median ? 5 Lo 95 percentiles) ar 0. 
0.75.X 12.24 and 36 h, in both treatment groups. The heparin group 
is subdivided on the basis of rhe activated partial thromboplastin 
time( (see Fig. I hr numbers and position of percentiles in different 
groups~. 
levels (<5W ng/ml) at baseline. D-dimer levels significantly 
increased during Jnd after lhromholysis in both the placebo 
and the heparin group. although the observed changes 
were less pronounced in the heparin group (p = O.wOI at 
3 h) (Fig. 3). In heparin-treated patients. D-dimer levels did 
not correlate with the level of anticoagulation or with pa- 
t‘Xy. 
Correlation between the level of anlicoagulation and sub- 
sequent coronary arlery patency. Concomitant intravenous 
administration of heparin with alteplase and aspirin was 
associated with a higher patency rate (TiMI grade 2 or 3) uf 
the infarct-related artery than was administration of placebo 
(80% vs. 71%. respectively, p = 0.05, Fig. 4). Among the 
PIgwe 4. Coronary perfusion status (Thrombolyns in Myocardial 
Infarction [TIM11 grades 0 lo 1) at angiography within 144 h in both 
trealment groups lheparin In = 1491, placebo In = 13211 and in the 
heparin subgroups classified on the bark ofaclivated partial throm- 
borrlaain times mm those with o~timrd In = 48). suboorimal (n = 401 
anb inadequate (n = 61) antic&dadon. The fig&r next to the 
bars present lhe percent of occluded vessels ITIMI grads 0 and I,. 
p values are for diiierences in TIM1 grades 0 and I WSYS TIMI 
grades 2 and 3. 
heparin-rreated patients. coronary artery patency (TIM1 
erade 2 or 31 was 90% (43 of481 in the subcram wth omlmal 
&ticoagulation compared with 80% I32 07 40; in those with 
suboptimal anticoagulation and 72% (44 of 61) m the sub- 
group with inadequate anticoagulation Ip = 0.02. optimal vs. 
inadequate anticoagulation). A complete set (five blood 
samples) ofactivated partial thmmbop!astm tnnes was avail- 
able in 85%. 73% and 80% respectively, of patients wth 
optimal, suboptimal and inadequate anticuagulation. 
In the placebo group. 22 patients had prolonged activated 
partial thromboplastin times; 8 were classified as having 
optimal and 14 as suboptimal anticoagulation by the defini- 
tion used for mtients allocated to heoarin theraw. The 
patency rates ii these patients were S& (4 of 8) ani’@+% (9 
of 141. resoectivelv. comrrared with 73% (80 of I101 in 
placeb+tre&d patients w;thout prolonged activated partial 
thromboplastin times. Eight patients in the placebo gruup 
were classified as having an occluded coronary arter) (TIM1 
grade 0) because of symptoms that led TV a second amjminis- 
tration of alteplase. 
Rearrent ischemia. Recurrent ischemia between the on- 
set of thrombolytic treatment and angiogmphy tended to be 
more frequent in the patients treated with placebo (17% 
than in those given heparin 111%) (Table 31. However. .K 
ddTcrcnce wac apparent between the incidence of recurrent 
~whemla in !he different subgroups. 
Oloedin~ complications. Aithough no difference wc ap- 
parent in bleeding complicationr between the heparin and 
pbcebo groups in this substudy. bleeding compiicdtmnr 
tended to be more frequent in the heparin group in the total 
patent population of the European Coopcrarivc Study 
Group wdy (8). Within the heparin group of the present 
,ub\!udy bleeding complications were more frequent in 
patients with optimal than in those with inadequate antico- 
aguiauon (Table 4). The majority of conplicatiaas were 
hematomas or prolonged bleeding at punctore sttes. Intra- 
cerebral bleeding was not observed in the patients of this 
cub,tudy. 
The need for early intravenous anticoagulation to 
mamram coronary anery patency after treatment wth 
alteplasr has been documented in three recent studies 
(6-N. The current substudy of the hepann trial of the 
European Cooperative Study Group shows that patency 
up to 6 days after initial therapy with alteplase is dependent 
01. the actual level of anticoagulation. A 90% patency rate 
after aItepla\e therapy can be achieved by optimal anticoag- 
uliltrnn wth mtravenous heparin. defined a activated partial 
thrumhoplastin times consistently above twice baseline val- 
ocs. 
In patients with evolving mywardial infarction after 
thrombolytac therapy. the disrupted endorhelium, the ath- 
emsckrotic surface and residual thmmbi at the site of initial 
coronary occlusion represent patent thmmbogenic stimuli 
that continue to activate the coagulation system. Further- 
mure. rhrombolytic therapy appears to be associated with in 
viva actiwtion of ;he coagulation system (17-21). This may 
result in reocclusion of the diseased artery, and may explain 
the somewhat higher reeocclusion rates after thrombolytic 
therapy wth more fibrin-selective drugs such as alteplase. 
compared with agents that result in extensive fibrincgen 
depleticn such as streptokinase or anistreplase. Heparin 
suppresses the enhanced fibrin generation during and after 
lhrombolytic thempy with altcplax (22). In eXPcrimenlal 
animal models ofth,&nbosn. th’rombolyvs with &eplasc is 
enhanced by concomitanl infusion of hewrin (23.24). In the 
present study, heparin administration Ii&d the increase in 
D-dimer during and after thrombalytic therapy, which sup. 
ports the hypothesis that heparin reduces lhe extent of 
activatmn of the coagulation system in patients receiving 
rhmmbolytic therapy. 
Level of anticoagutaiian and arterial pa .ncy. The present 
data from a representauvc subgroup of 28, patients pwtici- 
p&g in the double-blind hepxin versus placebo trial by the 
European Cooperative Study Group (8) indicate that a Rxed 
dose of 1 .WO U of hepari& provides adequate anticoagu- 
lation in only 32% of patients. A very high coronary patency 
rate (90%: 95% confidence interval 77% to 97%) was ob- 
served in patients wth optimal anticoagulation, defined as an 
activated partial thromboplastin time >200% of baseline 
value at all meas~,ements between 3 and 36 h. whereas 
patency in patients with inadequate anticoagulation was 
similar to that found in patients given placebo. Similarly, in 
the Heparin-Aspsin Reperfusion Trial (HART) (61 the acti- 
vated partial thromboplastin time after I8 h was more 
prolonged in patients with a patent comnary artery than in 
those with an occluded artery (25). Thus. to maintain coro- 
nary patency up to 144 h. altcplase requires intenx antico- 
agulation with intravenous heparin for at least 36 h. 
Eight patients who received placebo were classified as 
having “optimal an&coagulation.” It 1s likely that the acti- 
vatcd :?&I thromboplastin times in these patients ,ep,e- 
sent a prolonged etTect ofthrombolysis. It IS noteworthy that 
m this subgroup fibrinogen levels were the lowest and 
D-dimer levels the highest in the placebo group (Fig. 3). 
Recurrent isehemia. Surprisingly, no correlation ws found 
between the level of anticoagulation and the incidence of 
recurrent ischemia. This finding cw at least in part be 
explained by the relatively small number of patients but may 
ruppo,t the hypothesis that, in addition to adequate antics- 
agulation. potent antiplatelet agents other than aspirin may 
be needed to prevent recurrent &hernia, 
Bleeding complications. Conjunctive heparin and throm- 
bolytic treatment slightly increased the risk for bleeding 
complications when the total group of heparin-treated pa- 
tients in the European Cooperative Study Group trial is 
compared with the placebo group (8). In the present study, 
the irequency of bleeding complications, mainly hematomas 
at puncture sites, was higher in the subgroup with adequate 
anticoagulation than in patients with inadequate anticoagu- 
lation or in those receiving placebo, 
Conclusions. The present study show that, to sustain 
coronary patency, patients treated wrh alteplase require 
concomitant adequate anticoagulation with heparin. 
Whether this early and sustained paier,cy wilt translate to a 
rrduced mortality remains to be confirmed by large prospec- 
twe studies using alleplase and controlled anticoagulation 
with heparin. The Global Utilization of Streptokinase and 
tPA for Occluded Coronary Arteries GUSTO) trial (26) may 
help to clarify this issue. 

